8-K: Avidity Biosciences Announces Positive Initial Data for Delpacibart Zotadirsen in Duchenne Muscular Dystrophy Trial

Avidity Biosciences reported positive initial results from its EXPLORE44 trial, showing significant improvements in key biomarkers for Duchenne muscular dystrophy patients treated with delpacibart zotadirsen.

Summary

• Avidity Biosciences hosted an investor and analyst event on August 9, 2024, to discuss initial data from the EXPLORE44 trial of delpacibart zotadirsen (del-zota), formerly known as AOC 1044, for Duchenne muscular dystrophy (DMD) patients with mutations amenable to exon 44 skipping.
• The Phase 1/2 EXPLORE44 trial assessed the safety and tolerability of del-zota in 25 participants across two dose levels (5 mg/kg and 10 mg/kg).
• The 5 mg/kg cohort received del-zota every six weeks, or placebo.
• Del-zota demonstrated consistent delivery of phosphorodiamidate morpholino oligomers (PMO) to skeletal muscle, with a concentration of 200 nM after three doses at 5 mg/kg.
• The trial showed a 37% increase in exon 44 skipping at four months, with some participants showing up to a 66% increase.
• Dystrophin production increased by 25% of normal at four months, with total dystrophin restored up to 54% of normal.
• Creatine kinase levels were reduced to near normal, with greater than 80% reduction compared to baseline at four months.
• Del-zota showed favorable safety and tolerability, with most adverse events being mild or moderate.
• Two participants discontinued the study due to treatment-emergent adverse events: one due to anaphylaxis and one due to an infusion-related reaction.
• Enrollment in the EXPLORE44 trial is complete, and the company plans to enroll additional patients in an open-label extension study.
• Avidity intends to engage regulators to advance the development of del-zota and other exon-skipping DMD product candidates.

Sentiment

Score: 8

Explanation: The document presents very positive initial data from the EXPLORE44 trial, showing significant improvements in key biomarkers for DMD. The company's plans to expedite development and engage with regulators further contribute to a positive outlook. However, the risks associated with drug development and the two discontinuations due to adverse events temper the sentiment slightly.

Positives

• The study showed consistent delivery of PMO to skeletal muscle, which is crucial for the drug's effectiveness.
• The increase in exon 44 skipping is a positive sign that the drug is working as intended.
• The increase in dystrophin production is a key indicator of the drug's potential to improve muscle function.
• The significant reduction in creatine kinase levels suggests a positive impact on muscle damage.
• The favorable safety and tolerability profile is encouraging for further development.

Negatives

• Two participants discontinued the study due to treatment-emergent adverse events, including one case of anaphylaxis.
• One participant experienced a moderate infusion-related reaction, leading to discontinuation.

Risks

• Preliminary results of a clinical trial are not necessarily indicative of final results, and additional data may be inconsistent with the current findings.
• Unexpected adverse side effects or inadequate efficacy of the product candidate may delay or limit its development, regulatory approval, and commercialization.
• Avidity's approach to drug development using its AOC platform is unproven, and there is no guarantee of commercial success.
• There may be potential delays in the commencement, enrollment, data readouts, and completion of clinical trials.
• The company is dependent on third parties for preclinical and clinical testing and product manufacturing.
• Regulatory developments in the United States and foreign countries could impact the development and approval process.

Future Outlook

Avidity plans to engage with regulators to expedite the development of del-zota and advance additional exon-skipping DMD product candidates. They also plan to enroll additional patients in the EXPLORE44 Open-Label Extension study.

Management Comments

• Avidity is committed to partnering with the DMD community to efficiently advance treatment options.
• The company understands the responsibility to get treatments to patients as quickly as possible.

Industry Context

This announcement is significant in the context of the broader industry trend of developing targeted RNA therapeutics for rare genetic diseases. The positive results from the EXPLORE44 trial position Avidity as a key player in the DMD treatment landscape, potentially offering a new therapeutic option for patients with DMD44 mutations.

Comparison to Industry Standards

• The 200nM PMO concentration in muscle tissue after three doses is a strong result compared to other RNA therapeutics.
• The 37% increase in exon 44 skipping is a significant improvement compared to other exon-skipping approaches.
• The 25% increase in dystrophin production is a notable achievement, as many therapies struggle to achieve such levels.
• The greater than 80% reduction in creatine kinase levels is a substantial improvement compared to baseline, indicating a significant reduction in muscle damage.
• The safety profile of del-zota appears favorable compared to other experimental therapies for DMD, although further data is needed.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with DMD44 and their families may have increased hope for a new treatment option.
• Employees of Avidity may feel more optimistic about the company's future prospects.
• The positive results could attract potential partners and investors.

Next Steps

• Avidity plans to engage with regulators to discuss the most expeditious path to accelerated approval for del-zota.
• The company intends to enroll additional patients in the EXPLORE44 Open-Label Extension study.
• Avidity will pursue the advancement of additional exon-skipping DMD product candidates.

Key Dates

Keywords

Duchenne muscular dystrophy, DMD, delpacibart zotadirsen, del-zota, AOC 1044, exon 44 skipping, dystrophin, PMO, RNA therapeutics, EXPLORE44 trial, muscle, creatine kinase